Replies to post #167571 on Cytodyn Inc (CYDY)

[Northstar42]

Let's keep an open mind, there are different pathways to "Approval" and advancing LL for the benefit of patients and shareholders.
Though sometimes disappointed, I always like to think the best of people.

As a shareholder since 2015, I understand the frustration of waiting so long for LL to be recognized as the world class medication it is. More importantly, it is heart breaking to know that so many people could have been helped and weren't because LL was not available to them. We need to enlist the help of those who can facilitate positive change and hopefully we shareholders will play a constructive role in the process.

[Learning53]

Misiu,
It is concerning, and answers the continual chant of "Let Nader go!", but will it change things for the better?
The "environment" and background will remain the same or get worse, if the powers that rule sense the company's vulnerability. Further, there's a certain knowledge base that's fundamental and not easily subsumed "over night." You dump the current BOD, there'll be a significant problem with continuity and it's hard to imagine the newbies "hitting the ground running." And of course a key question remains - in what direction will they be running? We know which way Nader is going, even if he stumbles at times. Will the newbies be here to see Leronlimab brought to the good of humanity or CytoDyn turning a quick buck or what.

In the meantime, I suspect NP is not letting any grass grow under his feet.

For now...this is a "side show," let's stay focused on the Big picture.

Watching...